Developing An In Vivo CAR-T With Interius BioTherapeutics' Sianny Christanti and Babu Medi, Ph.D.

On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic. Follow Tyler Menichiello on LinkedIn:   / tmenichiello   Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Subscribe to our newsletters: https://www.bioprocessonline.com/user... -- Subscribe to the podcast! Apple - https://podcasts.apple.com/us/podcast... Spotify - https://open.spotify.com/show/3dvQdIL... YouTube -    • Better Biopharma